Thomas Henthorn
Concepts (377)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dronabinol | 8 | 2025 | 251 | 1.770 |
Why?
| | Marijuana Smoking | 6 | 2025 | 249 | 1.650 |
Why?
| | Ketamine | 6 | 2022 | 144 | 1.630 |
Why?
| | Respiratory Insufficiency | 3 | 2024 | 330 | 1.500 |
Why?
| | Models, Biological | 29 | 2025 | 1761 | 1.440 |
Why?
| | Cannabis | 6 | 2024 | 521 | 1.240 |
Why?
| | Hallucinogens | 4 | 2023 | 112 | 1.090 |
Why?
| | Fentanyl | 9 | 2024 | 126 | 1.050 |
Why?
| | Indocyanine Green | 16 | 2004 | 43 | 0.920 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2019 | 300 | 0.850 |
Why?
| | Analgesics, Opioid | 6 | 2025 | 1221 | 0.840 |
Why?
| | Methadone | 1 | 2025 | 130 | 0.800 |
Why?
| | Anesthetics, Intravenous | 5 | 2008 | 67 | 0.750 |
Why?
| | Dexmedetomidine | 1 | 2022 | 47 | 0.680 |
Why?
| | Analgesia | 2 | 2022 | 106 | 0.670 |
Why?
| | Analgesics | 3 | 2022 | 230 | 0.620 |
Why?
| | Red Meat | 1 | 2019 | 7 | 0.580 |
Why?
| | Cannabinoids | 4 | 2023 | 182 | 0.570 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 266 | 0.550 |
Why?
| | Antipyrine | 9 | 2004 | 12 | 0.550 |
Why?
| | Sleep Apnea Syndromes | 1 | 2019 | 98 | 0.550 |
Why?
| | Infusions, Intravenous | 13 | 2025 | 432 | 0.520 |
Why?
| | Thiopental | 9 | 2003 | 13 | 0.500 |
Why?
| | Acute Pain | 1 | 2018 | 58 | 0.500 |
Why?
| | Substance Abuse Detection | 4 | 2025 | 110 | 0.450 |
Why?
| | Tissue Distribution | 10 | 2020 | 334 | 0.430 |
Why?
| | Stereoisomerism | 3 | 2025 | 102 | 0.430 |
Why?
| | Coloring Agents | 7 | 2002 | 88 | 0.380 |
Why?
| | Pharmacokinetics | 4 | 2003 | 33 | 0.360 |
Why?
| | Humans | 73 | 2025 | 146342 | 0.330 |
Why?
| | Anesthetics, Local | 2 | 2025 | 106 | 0.330 |
Why?
| | Anesthetics, Dissociative | 2 | 2020 | 49 | 0.310 |
Why?
| | Verapamil | 3 | 2009 | 37 | 0.310 |
Why?
| | Lidocaine | 2 | 2023 | 55 | 0.310 |
Why?
| | Administration, Intravenous | 3 | 2025 | 172 | 0.300 |
Why?
| | Anesthesia, Intravenous | 3 | 2008 | 23 | 0.290 |
Why?
| | Loperamide | 1 | 2009 | 12 | 0.290 |
Why?
| | Organic Anion Transporters | 1 | 2009 | 13 | 0.290 |
Why?
| | Dose-Response Relationship, Drug | 10 | 2024 | 2022 | 0.280 |
Why?
| | Anesthetics, Inhalation | 2 | 2000 | 52 | 0.280 |
Why?
| | Dogs | 14 | 2006 | 517 | 0.270 |
Why?
| | Physician Impairment | 1 | 2007 | 15 | 0.260 |
Why?
| | Professional Misconduct | 1 | 2007 | 13 | 0.260 |
Why?
| | Wakefulness | 2 | 2019 | 170 | 0.260 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2008 | 48 | 0.260 |
Why?
| | Cardiac Output | 6 | 2004 | 176 | 0.260 |
Why?
| | Propofol | 2 | 2007 | 86 | 0.250 |
Why?
| | Liver Transplantation | 3 | 2002 | 751 | 0.240 |
Why?
| | Hypnotics and Sedatives | 3 | 2022 | 223 | 0.240 |
Why?
| | Inulin | 5 | 2000 | 12 | 0.240 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2025 | 9 | 0.230 |
Why?
| | Lumbosacral Plexus | 1 | 2025 | 10 | 0.230 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2017 | 344 | 0.230 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2025 | 29 | 0.230 |
Why?
| | Male | 47 | 2025 | 73396 | 0.230 |
Why?
| | Alfentanil | 4 | 1996 | 7 | 0.220 |
Why?
| | Endothelium, Vascular | 4 | 2002 | 952 | 0.220 |
Why?
| | Liver Function Tests | 2 | 2002 | 103 | 0.220 |
Why?
| | Amides | 1 | 2025 | 100 | 0.220 |
Why?
| | Pyrrolidines | 1 | 2025 | 127 | 0.210 |
Why?
| | Administration, Inhalation | 2 | 2024 | 567 | 0.210 |
Why?
| | Anesthesiology | 1 | 2007 | 178 | 0.210 |
Why?
| | Ketorolac | 2 | 2017 | 33 | 0.210 |
Why?
| | Academic Medical Centers | 1 | 2007 | 561 | 0.200 |
Why?
| | Splanchnic Circulation | 2 | 2002 | 11 | 0.200 |
Why?
| | Adult | 29 | 2025 | 41087 | 0.200 |
Why?
| | Nerve Block | 1 | 2025 | 114 | 0.200 |
Why?
| | Lung | 5 | 2009 | 4122 | 0.200 |
Why?
| | Glucuronides | 1 | 2022 | 18 | 0.180 |
Why?
| | Young Adult | 6 | 2025 | 14330 | 0.180 |
Why?
| | Substance-Related Disorders | 2 | 2007 | 1100 | 0.170 |
Why?
| | Genotype | 1 | 2025 | 1879 | 0.160 |
Why?
| | Plasma | 3 | 2020 | 222 | 0.160 |
Why?
| | Iatrogenic Disease | 1 | 2021 | 74 | 0.160 |
Why?
| | Hepatectomy | 1 | 2023 | 256 | 0.160 |
Why?
| | Hemodynamics | 5 | 2018 | 1114 | 0.160 |
Why?
| | Brain | 3 | 2009 | 2991 | 0.160 |
Why?
| | Midazolam | 3 | 2006 | 69 | 0.150 |
Why?
| | Milk, Human | 2 | 2021 | 176 | 0.150 |
Why?
| | Creatinine | 1 | 2022 | 511 | 0.150 |
Why?
| | Isoflurane | 1 | 2000 | 41 | 0.150 |
Why?
| | Middle Aged | 17 | 2025 | 36619 | 0.150 |
Why?
| | Pulmonary Circulation | 3 | 1997 | 431 | 0.150 |
Why?
| | Hepatic Encephalopathy | 1 | 1999 | 24 | 0.150 |
Why?
| | Vancomycin | 1 | 2020 | 96 | 0.150 |
Why?
| | Fibrinolysis | 2 | 1999 | 162 | 0.140 |
Why?
| | Neuromuscular Nondepolarizing Agents | 2 | 1997 | 34 | 0.140 |
Why?
| | Taurine | 1 | 2019 | 41 | 0.140 |
Why?
| | Metabolic Clearance Rate | 7 | 2024 | 115 | 0.140 |
Why?
| | Cystathionine beta-Synthase | 1 | 2019 | 65 | 0.140 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 140 | 0.140 |
Why?
| | Infusions, Intra-Arterial | 1 | 2018 | 61 | 0.140 |
Why?
| | Homocystinuria | 1 | 2019 | 62 | 0.140 |
Why?
| | Receptors, Opioid | 1 | 2018 | 21 | 0.140 |
Why?
| | Area Under Curve | 6 | 2008 | 335 | 0.140 |
Why?
| | Tandem Mass Spectrometry | 2 | 2021 | 576 | 0.140 |
Why?
| | Preoperative Care | 2 | 2020 | 396 | 0.130 |
Why?
| | Halothane | 1 | 1997 | 8 | 0.130 |
Why?
| | Female | 33 | 2025 | 79499 | 0.130 |
Why?
| | Anesthesia, Inhalation | 1 | 1997 | 14 | 0.130 |
Why?
| | Prochlorperazine | 2 | 2008 | 10 | 0.130 |
Why?
| | Bayes Theorem | 1 | 2020 | 426 | 0.130 |
Why?
| | Narcotics | 1 | 1998 | 57 | 0.130 |
Why?
| | Blood-Brain Barrier | 1 | 1999 | 169 | 0.130 |
Why?
| | Urine | 1 | 2017 | 63 | 0.130 |
Why?
| | Probability | 1 | 2018 | 309 | 0.130 |
Why?
| | Liver | 2 | 2023 | 1864 | 0.130 |
Why?
| | Mixed Function Oxygenases | 3 | 1999 | 43 | 0.130 |
Why?
| | Biomarkers | 6 | 2023 | 4340 | 0.120 |
Why?
| | Indicators and Reagents | 1 | 1996 | 105 | 0.120 |
Why?
| | Internship and Residency | 1 | 2007 | 1281 | 0.120 |
Why?
| | Animals | 23 | 2009 | 38107 | 0.120 |
Why?
| | Surgical Wound Infection | 1 | 2020 | 349 | 0.120 |
Why?
| | Pediatric Obesity | 1 | 2023 | 635 | 0.120 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 923 | 0.110 |
Why?
| | Cardiovascular Diseases | 1 | 2008 | 2219 | 0.110 |
Why?
| | Debrisoquin | 3 | 1989 | 3 | 0.110 |
Why?
| | Extracellular Space | 3 | 1999 | 118 | 0.110 |
Why?
| | Kinetics | 11 | 2002 | 1553 | 0.110 |
Why?
| | Neuromuscular Junction | 1 | 1995 | 65 | 0.110 |
Why?
| | Cattle | 5 | 2004 | 940 | 0.110 |
Why?
| | Amnesia | 2 | 2006 | 47 | 0.110 |
Why?
| | Arm | 1 | 1995 | 111 | 0.110 |
Why?
| | Rhodamine 123 | 3 | 2004 | 8 | 0.100 |
Why?
| | Carrier Proteins | 1 | 1998 | 728 | 0.100 |
Why?
| | Capillaries | 3 | 2025 | 123 | 0.100 |
Why?
| | Cannabinoid Receptor Agonists | 2 | 2023 | 44 | 0.100 |
Why?
| | Blood Volume | 4 | 2002 | 57 | 0.090 |
Why?
| | Smoking | 2 | 2020 | 1486 | 0.090 |
Why?
| | Gallamine Triethiodide | 2 | 1982 | 3 | 0.090 |
Why?
| | Dextromethorphan | 2 | 1989 | 24 | 0.090 |
Why?
| | Propranolol | 2 | 2004 | 44 | 0.090 |
Why?
| | Isoquinolines | 2 | 1989 | 44 | 0.090 |
Why?
| | Injections, Intravenous | 5 | 2011 | 197 | 0.090 |
Why?
| | Pulmonary Artery | 1 | 1998 | 1116 | 0.090 |
Why?
| | Drug Resistance, Multiple | 2 | 2001 | 25 | 0.080 |
Why?
| | Colorado | 1 | 2021 | 4595 | 0.080 |
Why?
| | Computer Simulation | 4 | 2023 | 1014 | 0.080 |
Why?
| | Hyperthermia, Induced | 2 | 2002 | 119 | 0.080 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2004 | 253 | 0.080 |
Why?
| | Models, Cardiovascular | 1 | 1992 | 194 | 0.080 |
Why?
| | Regional Blood Flow | 4 | 2004 | 507 | 0.080 |
Why?
| | Anesthesia | 2 | 1985 | 257 | 0.080 |
Why?
| | Polymorphism, Genetic | 2 | 1989 | 612 | 0.080 |
Why?
| | Cells, Cultured | 5 | 2004 | 4118 | 0.080 |
Why?
| | Reference Values | 3 | 2017 | 796 | 0.070 |
Why?
| | Limit of Detection | 2 | 2021 | 92 | 0.070 |
Why?
| | Levorphanol | 1 | 1989 | 2 | 0.070 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 1 | 1989 | 13 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1942 | 0.070 |
Why?
| | Dinoprost | 1 | 2009 | 51 | 0.070 |
Why?
| | Drug Administration Schedule | 2 | 2008 | 790 | 0.070 |
Why?
| | Microsomes, Liver | 1 | 1989 | 85 | 0.070 |
Why?
| | Pravastatin | 1 | 2009 | 45 | 0.070 |
Why?
| | Methohexital | 2 | 2000 | 2 | 0.070 |
Why?
| | Binding, Competitive | 1 | 2009 | 185 | 0.070 |
Why?
| | Biological Transport, Active | 2 | 1999 | 69 | 0.070 |
Why?
| | Child | 9 | 2025 | 22693 | 0.070 |
Why?
| | Piperidines | 2 | 2007 | 225 | 0.070 |
Why?
| | Bupivacaine | 1 | 1988 | 43 | 0.070 |
Why?
| | Body Water | 2 | 1999 | 23 | 0.070 |
Why?
| | Arousal | 1 | 1989 | 158 | 0.070 |
Why?
| | Heart Rate | 2 | 2009 | 846 | 0.070 |
Why?
| | Knee | 1 | 1988 | 81 | 0.070 |
Why?
| | Pain | 3 | 2024 | 790 | 0.070 |
Why?
| | Naloxone | 1 | 2009 | 139 | 0.060 |
Why?
| | Electroencephalography | 3 | 2009 | 576 | 0.060 |
Why?
| | Biological Availability | 3 | 2017 | 146 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 109 | 0.060 |
Why?
| | Adolescent | 9 | 2025 | 22557 | 0.060 |
Why?
| | Camptothecin | 1 | 2007 | 139 | 0.060 |
Why?
| | Cocaine | 1 | 1989 | 162 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 299 | 0.060 |
Why?
| | Time Factors | 5 | 2008 | 7109 | 0.060 |
Why?
| | Vecuronium Bromide | 2 | 1997 | 8 | 0.060 |
Why?
| | Acetaminophen | 2 | 2001 | 268 | 0.060 |
Why?
| | Arthroscopy | 1 | 1988 | 281 | 0.060 |
Why?
| | Quinazolines | 1 | 2007 | 267 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 585 | 0.060 |
Why?
| | Ultrasonics | 2 | 2004 | 50 | 0.060 |
Why?
| | Analysis of Variance | 2 | 2003 | 1298 | 0.060 |
Why?
| | Veins | 1 | 2025 | 68 | 0.050 |
Why?
| | Body Weight | 4 | 2024 | 968 | 0.050 |
Why?
| | Child, Preschool | 6 | 2025 | 11913 | 0.050 |
Why?
| | Pharmaceutical Preparations | 2 | 1986 | 172 | 0.050 |
Why?
| | Data Collection | 1 | 2007 | 650 | 0.050 |
Why?
| | Infant | 4 | 2024 | 10114 | 0.050 |
Why?
| | ErbB Receptors | 1 | 2007 | 636 | 0.050 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 1999 | 163 | 0.050 |
Why?
| | GABA Modulators | 1 | 2003 | 11 | 0.050 |
Why?
| | Consciousness | 1 | 2003 | 29 | 0.050 |
Why?
| | Pharmacology | 1 | 2003 | 10 | 0.050 |
Why?
| | Algorithms | 3 | 2003 | 1849 | 0.050 |
Why?
| | Anesthesia, General | 2 | 1996 | 124 | 0.050 |
Why?
| | Memory, Short-Term | 1 | 2006 | 276 | 0.050 |
Why?
| | Hematocrit | 2 | 2002 | 108 | 0.050 |
Why?
| | Semantics | 1 | 2003 | 96 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 1 | 2009 | 2537 | 0.050 |
Why?
| | Body Fluid Compartments | 1 | 1982 | 6 | 0.050 |
Why?
| | Reperfusion | 1 | 2002 | 53 | 0.050 |
Why?
| | Statistics as Topic | 2 | 1996 | 279 | 0.050 |
Why?
| | DNA | 1 | 2009 | 1421 | 0.040 |
Why?
| | Rats | 2 | 2009 | 5586 | 0.040 |
Why?
| | Body Fluids | 1 | 1982 | 70 | 0.040 |
Why?
| | Preanesthetic Medication | 3 | 1998 | 6 | 0.040 |
Why?
| | Aging | 3 | 2003 | 1996 | 0.040 |
Why?
| | Age Factors | 4 | 2017 | 3347 | 0.040 |
Why?
| | Liver Failure | 1 | 2002 | 79 | 0.040 |
Why?
| | Portal Vein | 1 | 2002 | 123 | 0.040 |
Why?
| | Hypoxia | 1 | 2009 | 1211 | 0.040 |
Why?
| | Memory | 1 | 2003 | 298 | 0.040 |
Why?
| | Postoperative Period | 1 | 2002 | 355 | 0.040 |
Why?
| | Hydroxylation | 3 | 1989 | 47 | 0.040 |
Why?
| | Point-of-Care Systems | 1 | 2002 | 185 | 0.040 |
Why?
| | Living Donors | 1 | 2002 | 216 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2017 | 588 | 0.040 |
Why?
| | Carbon Monoxide | 1 | 2000 | 82 | 0.040 |
Why?
| | Protein S | 1 | 1999 | 10 | 0.040 |
Why?
| | Hepatitis C | 1 | 2002 | 251 | 0.040 |
Why?
| | Antithrombin III | 1 | 1999 | 18 | 0.040 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2001 | 129 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2021 | 453 | 0.040 |
Why?
| | Lactones | 1 | 1999 | 60 | 0.040 |
Why?
| | Electromyography | 2 | 1997 | 428 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 846 | 0.040 |
Why?
| | Protein C | 1 | 1999 | 54 | 0.040 |
Why?
| | Tissue Donors | 1 | 2002 | 425 | 0.040 |
Why?
| | Nitrogen Isotopes | 1 | 1999 | 70 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2002 | 377 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2003 | 1149 | 0.040 |
Why?
| | Magnesium | 1 | 1999 | 155 | 0.040 |
Why?
| | Peptide Hydrolases | 1 | 1999 | 105 | 0.030 |
Why?
| | Homocysteine | 1 | 2019 | 152 | 0.030 |
Why?
| | Ultrasonography | 1 | 2002 | 788 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 1999 | 93 | 0.030 |
Why?
| | Urea | 1 | 1999 | 84 | 0.030 |
Why?
| | Neurosurgical Procedures | 1 | 2020 | 209 | 0.030 |
Why?
| | Oxidative Stress | 2 | 2019 | 1369 | 0.030 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 25 | 0.030 |
Why?
| | Brachial Artery | 1 | 2019 | 207 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2004 | 876 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 1998 | 0.030 |
Why?
| | Drug Therapy, Computer-Assisted | 1 | 1997 | 12 | 0.030 |
Why?
| | Infusion Pumps | 1 | 1997 | 33 | 0.030 |
Why?
| | Nebulizers and Vaporizers | 1 | 2017 | 63 | 0.030 |
Why?
| | Desipramine | 2 | 1989 | 10 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2020 | 260 | 0.030 |
Why?
| | Mathematical Computing | 1 | 1996 | 10 | 0.030 |
Why?
| | Aerosols | 2 | 2008 | 146 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2017 | 218 | 0.030 |
Why?
| | Body Mass Index | 2 | 2023 | 2458 | 0.030 |
Why?
| | Tonsillectomy | 1 | 1998 | 106 | 0.030 |
Why?
| | Pancuronium | 1 | 1995 | 5 | 0.030 |
Why?
| | Atracurium | 1 | 1995 | 14 | 0.030 |
Why?
| | Androstanols | 1 | 1995 | 30 | 0.030 |
Why?
| | Tourniquets | 1 | 1995 | 34 | 0.030 |
Why?
| | Prospective Studies | 2 | 2025 | 8123 | 0.030 |
Why?
| | Renal Dialysis | 1 | 1999 | 461 | 0.030 |
Why?
| | Phenotype | 4 | 1989 | 3206 | 0.020 |
Why?
| | Energy Metabolism | 1 | 1999 | 930 | 0.020 |
Why?
| | Melanoma | 1 | 1999 | 765 | 0.020 |
Why?
| | Software | 1 | 1998 | 676 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2024 | 6460 | 0.020 |
Why?
| | Mathematics | 1 | 1992 | 102 | 0.020 |
Why?
| | Coronary Circulation | 1 | 1992 | 134 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 1999 | 2921 | 0.020 |
Why?
| | Injections | 1 | 1992 | 201 | 0.020 |
Why?
| | Drug Interactions | 2 | 2004 | 405 | 0.020 |
Why?
| | Pentobarbital | 2 | 1996 | 17 | 0.020 |
Why?
| | Protein Binding | 2 | 2009 | 2244 | 0.020 |
Why?
| | Administration, Rectal | 2 | 2001 | 14 | 0.020 |
Why?
| | Mephenytoin | 1 | 1989 | 1 | 0.020 |
Why?
| | Hydantoins | 1 | 1989 | 6 | 0.020 |
Why?
| | Tumor Cells, Cultured | 2 | 2001 | 882 | 0.020 |
Why?
| | Spain | 1 | 1989 | 50 | 0.020 |
Why?
| | Diazepam | 1 | 1989 | 32 | 0.020 |
Why?
| | Elective Surgical Procedures | 1 | 2011 | 216 | 0.020 |
Why?
| | Succinic Acid | 1 | 2009 | 46 | 0.020 |
Why?
| | Infusions, Parenteral | 3 | 1984 | 47 | 0.020 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 1989 | 33 | 0.020 |
Why?
| | Free Radicals | 1 | 2009 | 104 | 0.020 |
Why?
| | Diffusion | 1 | 1989 | 119 | 0.020 |
Why?
| | Drug Tolerance | 1 | 1989 | 100 | 0.020 |
Why?
| | Injections, Intra-Articular | 1 | 1988 | 64 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 1999 | 2219 | 0.020 |
Why?
| | Aged | 6 | 1999 | 26432 | 0.020 |
Why?
| | Tubocurarine | 1 | 1987 | 6 | 0.020 |
Why?
| | Neuromuscular Blocking Agents | 1 | 1987 | 28 | 0.020 |
Why?
| | Drug Combinations | 1 | 1989 | 400 | 0.020 |
Why?
| | Inflammation | 1 | 2019 | 2919 | 0.020 |
Why?
| | Lactic Acid | 1 | 2009 | 295 | 0.020 |
Why?
| | Double-Blind Method | 2 | 2006 | 2070 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 238 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1989 | 1041 | 0.020 |
Why?
| | Glutathione | 1 | 2009 | 369 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2009 | 348 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2008 | 615 | 0.010 |
Why?
| | Mice, Nude | 1 | 2007 | 668 | 0.010 |
Why?
| | Cardiopulmonary Bypass | 1 | 1987 | 217 | 0.010 |
Why?
| | Colonic Neoplasms | 1 | 2007 | 259 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 1989 | 1075 | 0.010 |
Why?
| | Anesthetics | 1 | 1986 | 100 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2007 | 1244 | 0.010 |
Why?
| | Altitude | 1 | 2009 | 469 | 0.010 |
Why?
| | Aminocaproates | 1 | 1984 | 3 | 0.010 |
Why?
| | Aminocaproic Acid | 1 | 1984 | 4 | 0.010 |
Why?
| | Cell Membrane Permeability | 1 | 2004 | 88 | 0.010 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2004 | 76 | 0.010 |
Why?
| | Sucrose | 1 | 2004 | 113 | 0.010 |
Why?
| | Etomidate | 1 | 1983 | 23 | 0.010 |
Why?
| | Metabolomics | 1 | 2009 | 738 | 0.010 |
Why?
| | Factor Analysis, Statistical | 1 | 2003 | 298 | 0.010 |
Why?
| | Memory Disorders | 1 | 2003 | 198 | 0.010 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 1999 | 124 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2004 | 340 | 0.010 |
Why?
| | Imidazoles | 1 | 1983 | 245 | 0.010 |
Why?
| | Capillary Permeability | 1 | 1982 | 133 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 142 | 0.010 |
Why?
| | Ultrasonic Therapy | 1 | 2001 | 16 | 0.010 |
Why?
| | Blotting, Western | 1 | 2004 | 1177 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2003 | 368 | 0.010 |
Why?
| | Cerebrovascular Circulation | 1 | 2004 | 293 | 0.010 |
Why?
| | Procainamide | 1 | 1981 | 6 | 0.010 |
Why?
| | United States | 1 | 2019 | 16136 | 0.010 |
Why?
| | Hot Temperature | 1 | 2004 | 396 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 1993 | 8391 | 0.010 |
Why?
| | Cyclosporins | 1 | 2000 | 71 | 0.010 |
Why?
| | Theophylline | 1 | 1980 | 41 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 165 | 0.010 |
Why?
| | Blood Proteins | 1 | 1982 | 239 | 0.010 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2001 | 141 | 0.010 |
Why?
| | Synaptic Transmission | 1 | 1982 | 294 | 0.010 |
Why?
| | Plasma Substitutes | 1 | 1999 | 6 | 0.010 |
Why?
| | Bryostatins | 1 | 1999 | 2 | 0.010 |
Why?
| | Hypovolemia | 1 | 1999 | 6 | 0.010 |
Why?
| | Anti-Arrhythmia Agents | 1 | 1981 | 144 | 0.010 |
Why?
| | Cell Division | 1 | 2001 | 736 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2007 | 3545 | 0.010 |
Why?
| | Macrolides | 1 | 1999 | 68 | 0.010 |
Why?
| | Platelet Activation | 1 | 1999 | 99 | 0.010 |
Why?
| | Doxorubicin | 1 | 2001 | 416 | 0.010 |
Why?
| | Dialysis Solutions | 1 | 1999 | 23 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1999 | 161 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 2000 | 419 | 0.010 |
Why?
| | Cell Survival | 1 | 2001 | 1105 | 0.010 |
Why?
| | Suppositories | 1 | 1997 | 3 | 0.010 |
Why?
| | Neuromuscular Depolarizing Agents | 1 | 1997 | 6 | 0.010 |
Why?
| | Intraoperative Period | 1 | 1997 | 69 | 0.010 |
Why?
| | Erythrocytes | 1 | 1982 | 750 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2001 | 893 | 0.010 |
Why?
| | Administration, Oral | 1 | 1998 | 872 | 0.010 |
Why?
| | Cognition | 1 | 2003 | 1292 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2007 | 3926 | 0.010 |
Why?
| | Unconsciousness | 1 | 1994 | 24 | 0.010 |
Why?
| | Half-Life | 1 | 1993 | 157 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2007 | 11821 | 0.010 |
Why?
| | Mice | 2 | 2007 | 18297 | 0.010 |
Why?
| | Body Height | 1 | 1993 | 205 | 0.010 |
Why?
| | Movement | 1 | 1993 | 290 | 0.010 |
Why?
| | Kidney | 1 | 1999 | 1498 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 1999 | 3416 | 0.000 |
Why?
| | Regression Analysis | 1 | 1993 | 999 | 0.000 |
Why?
| | Nordazepam | 1 | 1989 | 1 | 0.000 |
Why?
| | Benzodiazepines | 1 | 1989 | 158 | 0.000 |
Why?
| | Hip Prosthesis | 1 | 1987 | 43 | 0.000 |
Why?
| | Sufentanil | 1 | 1986 | 2 | 0.000 |
Why?
| | Sex Factors | 1 | 1993 | 2107 | 0.000 |
Why?
| | Methods | 1 | 1986 | 68 | 0.000 |
Why?
| | Hypothermia, Induced | 1 | 1987 | 96 | 0.000 |
Why?
| | Droperidol | 1 | 1983 | 4 | 0.000 |
Why?
| | Reflex, Pupillary | 1 | 1983 | 6 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1987 | 1064 | 0.000 |
Why?
| | Acecainide | 1 | 1981 | 2 | 0.000 |
Why?
| | Aminophylline | 1 | 1980 | 12 | 0.000 |
Why?
| | Respiration | 1 | 1981 | 208 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1981 | 563 | 0.000 |
Why?
| | Asthma | 1 | 1980 | 1800 | 0.000 |
Why?
|
|
Henthorn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|